King Pharma



Sort by : relevance - date
3Vote!

ZymoGenetics, King Pharma Brawl Over Drugs to Control Surgical Bleeding

Xconomy (Free subscription) | 11/09/2009

ZymoGenetics started really playing hardball with King Pharmaceuticals in August, and now a high-and-tight fastball has come right back at the Seattle biotech company. The projectile in question is a lawsuit filed on November 2 by Bristol, TN-based King in the U.S. District Court in Eastern Tennessee; the suit accuses ZymoGenetics of false advertising, unfair competition, [...]

5Vote!

King Pharma Income Statement Analysis for September 2009 Quarter

SeekingAlpha.com (Free subscription) | 11/09/2009

Neil Carvin submits: King Pharmaceuticals, Inc. (NYSE: KG ) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year. On a non - GAAP (" pro forma " or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference between GAAP and non-GAAP Net Income was $46 million in the latest quarter. The most substantial...

Explore : Finance